Emma Guttman-Yassky

Emma Guttman-Yassky
Occupation(s)System Chair, Department of Dermatology, and the Waldman professor of dermatology and immunology, at the Icahn School of Medicine at Mount Sinai in New York.
Academic background
Education
Academic work
Disciplinedermatology, immunology
Sub-disciplineinflammatory skin disease
InstitutionsIcahn School of Medicine at Mount Sinai
Websiteprofiles.mountsinai.org/emma-guttman

Emma Guttman-Yassky is the System Chair of the Department of Dermatology and Waldman professor of dermatology and immunology at the Icahn School of Medicine at Mount Sinai in New York.[1] She is also director of the Asness Family Center for Excellence in Eczema, Mount Sinai Clinique Healthy Skin Dermatology Center and its Inflammatory Skin Disease Laboratory.[2][3]

According to Google Scholar she has an h-index of 106.[4]

Education

Guttman received her MD from Sackler School of Medicine in 1996. While completing her dermatology residency at the Rambam Medical Center, she pursued postgraduate studies in dermatology and basic sciences at the Sackler Faculty of Medicine. She went on to study internal medicine during her translational year at Memorial Sloan-Kettering Cancer Center in 2008. Before completing her dermatology residency at Weill Cornell Medical College in 2011, she also received her PhD in 2010 for her thesis on clinical and molecular aspects of Classic Kaposi’s Sarcoma at Bar-Ilan University.

Research

Dr. Guttman’s research made breakthrough discoveries on the immunologic basis of atopic dermatitis/eczema (AD) and alopecia areata (AA) as well as scarring alopecia. She is the first to identify in humans a distinct population of T-cells that independently produce IL-22 without co-producing IL-17 (as in mice), framing the concept that in humans, Th22 T-cells are distinct from Th17 T-cells.[5] Guttman has also designed a clinical trial that was funded by the NIH/NIAMS (UM1AR063917-01), utilizing an anti-IL-22 antibody - the first to explore the biological effects of blocking IL-22 on AD.[6] Additionally, she established the reversibility of AD and defined a series of therapeutic response-biomarkers that are now implemented in testing of novel therapeutics.

Dr. Guttman’s research identified that different AD subsets (intrinsic/extrinsic, pediatric/adult, and differences between AD patients from different racial/ethnic backgrounds) differ in their immune polarization, enabling a personalized medicine approach.[7][8] Her lab is currently studying the contribution of specific Th2-, Th17/IL-23-, and Th22-targeting treatments to different AD phenotypes.[2]

More recently, her studies extended to other inflammatory skin diseases (alopecia areata/AA and contact dermatitis), where they have also made significant observations. They have shown that human allergic contact dermatitis is not a single entity, and various allergens (i.e., nickel, fragrance) induce differential immune polarizations.[9] They have also redefined the molecular maps of AA, associating its molecular profile with Th1/IFN, Th2, and IL-23 activation.[10] They initiated clinical trials with specific (dupilumab, targeting only the Th2 immune pathway) or broad agents that are now identifying which cytokine pathways are pathogenic in AA.  

References

  1. ^ "Emma Guttman - Dermatology". Mount Sinai Health System. Retrieved 12 March 2023.
  2. ^ a b "Laboratory of Inflammatory Skin Diseases". Laboratory of Inflammatory Skin Diseases |. Retrieved 12 March 2023.
  3. ^ "Mount Sinai to Receive $5 Million Gift From the Asness Family to Advance Eczema and Allergy Research and Treatment". 30 June 2025.
  4. ^ "Emma Guttman-Yassky". Google Scholar.
  5. ^ Nograles, Kristine E.; Zaba, Lisa C.; Shemer, Avner; Fuentes-Duculan, Judilyn; Cardinale, Irma; Kikuchi, Toyoko; Ramon, Michal; Bergman, Reuven; Krueger, James G.; Guttman-Yassky, Emma (1 June 2009). "IL-22–producing "T22" T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17–producing TH17 T cells". Journal of Allergy and Clinical Immunology. 123 (6): 1244–1252.e2. doi:10.1016/j.jaci.2009.03.041. PMC 2874584. PMID 19439349.
  6. ^ Guttman-Yassky, Emma; Brunner, Patrick M.; Neumann, Avidan U.; Khattri, Saakshi; Pavel, Ana B.; Malik, Kunal; Singer, Giselle K.; Baum, Danielle; Gilleaudeau, Patricia; Sullivan-Whalen, Mary; Rose, Sharon; Jim On, Shelbi; Li, Xuan; Fuentes-Duculan, Judilyn; Estrada, Yeriel (1 May 2018). "Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial". Journal of the American Academy of Dermatology. 78 (5): 872–881.e6. doi:10.1016/j.jaad.2018.01.016. PMC 8711034. PMID 29353025.
  7. ^ Silverberg, Jonathan I.; Guttman-Yassky, Emma; Thaçi, Diamant; Irvine, Alan D.; Stein Gold, Linda; Blauvelt, Andrew; Simpson, Eric L.; Chu, Chia-Yu; Liu, Zhuqing; Gontijo Lima, Renata; Pillai, Sreekumar G.; Seneschal, Julien (23 March 2023). "Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis". New England Journal of Medicine. 388 (12): 1080–1091. doi:10.1056/NEJMoa2206714. ISSN 0028-4793.
  8. ^ Guttman-Yassky, Emma; Simpson, Eric L; Reich, Kristian; Kabashima, Kenji; Igawa, Ken; Suzuki, Tetsuya; Mano, Hirotaka; Matsui, Takeshi; Esfandiari, Ehsanollah; Furue, Masutaka (9 December 2022). "An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study". The Lancet. 401 (10372): 204–214. doi:10.1016/S0140-6736(22)02037-2.
  9. ^ Dhingra, Nikhil; Shemer, Avner; Correa da Rosa, Joel; Rozenblit, Mariya; Fuentes-Duculan, Judilyn; Gittler, Julia K.; Finney, Robert; Czarnowicki, Tali; Zheng, Xiuzhong; Xu, Hui; Estrada, Yeriel D.; Cardinale, Irma; Suárez-Fariñas, Mayte; Krueger, James G.; Guttman-Yassky, Emma (1 August 2014). "Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response". Journal of Allergy and Clinical Immunology. 134 (2): 362–372. doi:10.1016/j.jaci.2014.03.009.
  10. ^ Suárez-Fariñas, Mayte; Ungar, Benjamin; Noda, Shinji; Shroff, Anjali; Mansouri, Yasaman; Fuentes-Duculan, Judilyn; Czernik, Annette; Zheng, Xiuzhong; Estrada, Yeriel D.; Xu, Hui; Peng, Xiangyu; Shemer, Avner; Krueger, James G.; Lebwohl, Mark G.; Guttman-Yassky, Emma (1 November 2015). "Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing". Journal of Allergy and Clinical Immunology. 136 (5): 1277–1287. doi:10.1016/j.jaci.2015.06.032.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.